Dicerna Pharmaceuticals (NASDAQ:DRNA) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.15), Fidelity Earnings reports. Dicerna Pharmaceuticals had a negative return on equity of 50.30% and a negative net margin of 737.93%. The firm had revenue of $8.04 million for the quarter, compared to analyst estimates of $11.70 million.
Shares of NASDAQ:DRNA traded up $0.09 during trading on Friday, reaching $17.69. 824,800 shares of the stock were exchanged, compared to its average volume of 465,156. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.65 and a quick ratio of 3.65. Dicerna Pharmaceuticals has a 1-year low of $9.31 and a 1-year high of $18.39. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -14.74 and a beta of 2.29. The stock has a fifty day moving average of $15.51 and a two-hundred day moving average of $14.24.
A number of brokerages have recently weighed in on DRNA. Leerink Swann upped their target price on Dicerna Pharmaceuticals from $22.00 to $26.00 in a research report on Friday, November 1st. Zacks Investment Research raised Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 5th. ValuEngine raised Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday. BidaskClub raised Dicerna Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, Robert W. Baird began coverage on Dicerna Pharmaceuticals in a research report on Tuesday, October 29th. They set an “outperform” rating and a $27.00 target price on the stock. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Dicerna Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $22.50.
In other Dicerna Pharmaceuticals news, CFO John B. Green sold 12,500 shares of Dicerna Pharmaceuticals stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $18.00, for a total transaction of $225,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider James B. Weissman sold 14,680 shares of Dicerna Pharmaceuticals stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $13.07, for a total value of $191,867.60. Following the transaction, the insider now owns 9,800 shares of the company’s stock, valued at approximately $128,086. The disclosure for this sale can be found here. Insiders have sold 42,180 shares of company stock worth $686,868 over the last 90 days. 21.28% of the stock is currently owned by corporate insiders.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
Read More: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.